BUDGET IMPACT ANALYSIS OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN THE UNITED STATES

被引：0
|
作者：
Nesheim, J. [1 ]
Chen, J., V [2 ]
Gahn, J. C. [2 ]
Mudd, P. [3 ]
机构：
[1] Urovant Sci, Irvine, CA USA
[2] Med Decis Modeling, Indianapolis, IN USA
[3] Urovant Sci, Durham, NC USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK5
引用
下载
收藏
页码：S234 / S235
页数：2
相关论文
共 50 条
  • [21] TREATMENT NAVIGATOR IMPACT ON UTILIZATION OF ONABOTULINUMTOXINA AS THIRD LINE TREATMENT IN OVERACTIVE BLADDER: A RETROSPECTIVE DATABASE STUDY IN THE UNITED STATES
    Enemchukwu, E.
    Miles-Thomas, J.
    Syan, R.
    Abraham, N.
    Madaj, K.
    Spenta, Anson K.
    Boroujerdi, A.
    Bai, Z.
    Luo, L.
    Newman, D.
    NEUROUROLOGY AND URODYNAMICS, 2021, 40 : S98 - S99
  • [22] BUDGET IMPACT ANALYSIS OF ESKETAMINE IN TREATMENT-RESISTANT DEPRESSION IN THE UNITED STATES
    Le, H. H.
    Zhang, Q.
    Sheehan, J. J.
    VALUE IN HEALTH, 2019, 22 : S229 - S230
  • [23] TALTZ® (IXEKIZUMAB) FOR TREATMENT OF PSORIATIC ARTHRITIS IN THE UNITED STATES: A BUDGET IMPACT ANALYSIS
    Murage, M.
    Panchmatia, H.
    Patel, S.
    Birt, J.
    Gellet, A. M.
    Sprabery, A. T.
    Malatestinic, B.
    Atiya, B.
    Kern, S.
    Kadambi, A.
    VALUE IN HEALTH, 2020, 23 : S220 - S221
  • [24] BUDGET IMPACT ANALYSIS OF NEFECON FOR THE TREATMENT OF PRIMARY IGA NEPHROPATHY IN THE UNITED STATES
    Hwang, S.
    Ramjee, L.
    Patel, M.
    Ngai, C.
    Tremblay, G.
    VALUE IN HEALTH, 2022, 25 (07) : S400 - S400
  • [25] Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
    Michael J. Kennelly
    Thomas Rhodes
    Cynthia J. Girman
    Elizabeth Thomas
    Denise Shortino
    Paul N. Mudd
    Advances in Therapy, 2021, 38 : 5452 - 5464
  • [26] Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder
    Edmondson, Scott D.
    Zhu, Cheng
    Kar, Nam Fung
    Di Salvo, Jerry
    Nagabukuro, Hiroshi
    Sacre-Salem, Beatrice
    Dingley, Karen
    Berger, Richard
    Goble, Stephen D.
    Morriello, Gregori
    Harper, Bart
    Moyes, Christopher R.
    Shen, Dong-Ming
    Wang, Liping
    Ball, Richard
    Fitzmaurice, Aileen
    Frenkl, Tara
    Gichuru, Loise N.
    Ha, Sookhee
    Hurley, Amanda L.
    Jochnowitz, Nina
    Levorse, Dorothy
    Mistry, Shruty
    Miller, Randy R.
    Ormes, James
    Salituro, Gino M.
    Sanfiz, Anthony
    Stevenson, Andra S.
    Villa, Katherine
    Zamlynny, Beata
    Green, Stuart
    Struthers, Mary
    Weber, Ann E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (02) : 609 - 623
  • [27] Economic Costs of Overactive Bladder in the United States REPLY
    Ganz, Michael L.
    Pashos, Chris L.
    Smalarz, Amy M.
    Krupski, Tracey L.
    Anger, Jennifer T.
    Hu, Jim C.
    Wittrup-Jensen, Kim U.
    UROLOGY, 2010, 75 (03) : 533 - 533
  • [28] Estimated economic costs of overactive bladder in the United States
    Hu, TW
    Wagner, TH
    Bentkover, JD
    LeBlanc, K
    Piancentini, A
    Stewart, WF
    Corey, R
    Zhou, SZ
    Hunt, TL
    UROLOGY, 2003, 61 (06) : 1123 - 1128
  • [29] Economic Costs of Overactive Bladder in the United States COMMENT
    Cespedes, R. Duane
    UROLOGY, 2010, 75 (03) : 532 - 532
  • [30] Optimizing Nonsurgical Treatments of Overactive Bladder in the United States
    Brucker, Benjamin M.
    Lee, Richard K.
    Newman, Diane K.
    UROLOGY, 2020, 145 : 52 - 59
12345